FDA rejects cancer therapy for rare post-transplant disease

Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …

AI Summary: The FDA has again rejected Atara’s cell therapy aimed at treating rare post‐transplant complications linked to Epstein–Barr virus. Despite high hopes for this innovative approach, regulatory concerns remain over its safety and efficacy—clearly a “repeat performance” in the world of breakthrough therapies.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month

FDA launches individualized therapy framework for ultra-rare diseases / 3 months

FDA makes one pivotal trial the default for drug approvals / 3 months

FDA refuses to review Moderna mRNA flu vaccine application / 3 months

Boehringer gains fast approval for first‑line lung cancer drug via voucher program / 3 months

FDA commissioner Marty Makary resigns amid mounting scrutiny / 19 days

World Cancer Day Global Awareness Campaign / 3 months